Authors

  • Muminov D.K.
    MD, PhD, DSc., Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
  • Kenjaev O.O
    Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan

DOI:

https://doi.org/10.37547/TAJMSPR/Volume06Issue09-07

Keywords:

Bronchial asthma pulmonary hypertension cor pulmonale

Abstract

Bronchial asthma (BA) is a serious medical problem. The prevalence of asthma is increasing in most countries. Deterioration of pulmonary function is as strong a predictor of cardiovascular mortality as major cardiovascular risk factors. In this review, we tried to reflect the current current understanding of the adverse effects of asthma on cardiovascular remodeling.


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN

2689-1026)

VOLUME 06 ISSUE09

41

https://www.theamericanjournals.com/index.php/tajmspr

PUBLISHED DATE: - 30-09-2024

DOI: -

https://doi.org/10.37547/TAJMSPR/Volume06Issue09-07

PAGE NO.: - 41-44

FEATURES OF CENTRAL HEMODYNAMICS IN
PATIENTS WITH BRONCHIAL ASTHMA


Muminov D.K.

MD, PhD, DSc., Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan

Kenjaev O.O

Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan

INTRODUCTION

In the last decade, chronic nonspecific lung
diseases have taken third place in terms of
prevalence, morbidity and mortality among other
types of pathology. According to 2020

2023 World

Health Organization (WHO) estimates, nearly 262
million people worldwide suffered from bronchial
asthma, resulting in 455,000 deaths [1].

Bronchial asthma (BA) is a heterogeneous disease
characterized by chronic inflammation of the
airways, the presence of respiratory symptoms
such as wheezing, shortness of breath, chest
congestion and cough, which vary in time and
intensity, and occur together with variable airway
obstruction [1,2]. Based on the pathogenesis of
asthma, a number of cytokines and growth factors
relevant to the chronicity of airway inflammation
are produced by normal resident cells of the
bronchial tree (fibroblasts, myofibroblasts,
epithelial cells and smooth muscle cells).

Fibroblasts play a key role in airway remodeling
and inflammation. They produce collagen,
reticular and elastic fibers, proteoglycans and
glycoproteins. Myofibroblasts promote tissue
remodeling by releasing interstitial collagen,
fibronectin and laminin, and producing growth
factors for blood vessels, nerves and smooth
muscle [3]. In bronchial asthma, the number of
myofibroblasts increases and their number
correlates with the thickness of the reticular
basement membrane. Thus, as a result of the
pathological process in bronchial asthma, the
reversible component of bronchial obstruction
predominates, which consists of contraction of
smooth muscles, edema of the mucous membrane,
and obstruction of the bronchial lumen by mucus.
However, with long-term inflammation in the
bronchi, wall remodeling and proliferation of
connective tissue (fibrosis) occurs, which is an
irreversible part of bronchial obstruction. This in

RESEARCH ARTICLE

Open Access

Abstract


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN

2689-1026)

VOLUME 06 ISSUE09

42

https://www.theamericanjournals.com/index.php/tajmspr

turn will lead to multiple complications from the
cardiovascular system [3,4].

Frequent exacerbations of attacks in asthma are
most clearly demonstrated by the close anatomical
and functional connection between the heart and
lungs. As a result, the problem goes from
pulmonary to cardiopulmonary. In patients with
asthma, changes in the cardiovascular system are
often recorded with the development of
pulmonary hypertension, damage predominantly
to the right side with the formation of chronic
pulmonary heart disease, the development of
myocardial

ischemia

and

heart

rhythm

disturbances. The issues of the combined course of
cardiovascular diseases (CVD) and asthma are
actively discussed in the literature. [5]. Cardiac
remodeling, which occurs in response to damage,
leading to a change in its geometry and impaired
contractility, ultimately determines the prognosis
of life for patients with chronic obstructive
pulmonary pathology. Despite the fact that the
main function of the circulatory system is
transport, its participation in physiological and
pathological processes in the div is very diverse.
It should be noted that the clinical, functional and
morphological changes that occur in the
cardiovascular system during inflammation, as a
rule, represent a complex chain of cause-and-effect
and closely related manifestations of pathology
[6,7]. Therefore, pathological changes that can be
objectively assessed are usually the result of the
simultaneous influence of multiple factors such as
hypoxemia, hypercapnia, bronchial obstruction
and associated ventilation disorders, intoxication
with products of altered tissue metabolism,
pathological effects of biologically active
substances, and disturbances in the rheological
properties of blood [8]. The severity of changes in
the cardiovascular system and, accordingly, its
clinical manifestations depend on the prevalence

of bronchial lesions, as well as the phase of the
process. It is known that changes in the pulmonary
circulation in patients with bronchial asthma can
be associated with both disturbances of central
hemodynamics and disorders of pulmonary
microcirculation.

According to the observations of many authors, in
patients with mild impairments in the function of
external respiration, normal levels of oxygen
tension in the arterial blood, pressure in the
pulmonary artery and minute blood volume do not
exceed normal figures [3,9]. Against the
background of repeated exacerbations, with the
progression of respiratory dysfunction, changes in
hemodynamics also become more pronounced.
Increasing disturbances in bronchial obstruction,
diffusion capacity and lung volume parameters,
leading to chronic hypoxemia and hypercapnia,
can cause the development of moderate
pulmonary hypertension at rest and an increase in
right ventricular filling pressure [10]. Systolic and
diastolic function of the right ventricle in patients
with asthma. Previous studies have revealed that
the state of diastolic function of the right ventricle
in asthma depends on the severity of the
underlying disease, the formation of the level of
afterload, the values of pulmonary hypertension
and the severity of enlargement and hypertrophy
of the right ventricle. In various groups of patients
with asthma, pathological load against the
background of the lack of pharmacotherapeutic
control of asthma (increased resistance in the
pulmonary circulation, myocardial hypoxia) leads
to structural and functional changes in the
pancreas [11]. An increase in the severity of
bronchial asthma naturally leads to even more
pronounced remodeling of the right ventricle and
changes in regional contraction indices at the
inflow level. The dependence of progressive
changes in the diastolic function of the right


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN

2689-1026)

VOLUME 06 ISSUE09

43

https://www.theamericanjournals.com/index.php/tajmspr

ventricle on the severity of asthma has been
established. Pulmonary hypertension in patients
with moderate and severe asthma is associated
with the development of diastolic dysfunction in
the right ventricle and changes in the
morphometric parameters of the right ventricle
[4,12].

It should be noted that the appearance of
hypertrophy, dilatation and subsequent failure of
the right ventricle can be recorded at relatively low
pressure levels in the pulmonary artery, not
exceeding 35 mmHg. This may indicate that
pulmonary hypertension is not the only cause of
the formation of chronic cor pulmonale [13]. In the
diagnosis of asthma, correlation analysis data in
the group of asthmatics with moderate disease
showed an inverse relationship between the
degree of right ventricular hypertrophy (RVH) and
the FEV1/FVC value. Outside of exacerbation of the
disease, a negative relationship was revealed
between RVH and FEV1. In a cohort of patients
with severe asthma during an exacerbation, a
negative relationship between FEV1/FVC and the
diameter of the pulmonary trunk was also
recorded

[7].

Correlation

analysis

of

echocardiographic

data

with

div

plethysmography data in patients with moderate
asthma during exacerbations established a
negative relationship between residual lung
volume and maximum late filling rate. In patients
with severe asthma, a significant positive
relationship was found between the thickness of
the anterior wall of the right ventricle and the
residual lung volume (RLV), the RLV/RLV ratio, as
well as between the RLV and end-diastolic
pressure in the pulmonary artery. During the
period of remission of the disease in the group of
patients with moderate asthma, a positive
relationship was established between expiratory
air resistance and the value of MPAP. A

combination of changes in the shape of the right
ventricular cavity (an increase in the ratio of
transverse to longitudinal dimensions) with the
development of diastolic dysfunction of the right
ventricle was also identified. The identified
disorders are a reflection of the general process
associated with the structural and functional
remodeling of the right heart in patients with
bronchial asthma. Changes in the right ventricular
myocardium are closely associated with persistent
bronchial obstruction, impaired lung volumes, and
chronic inflammation present in the airways. It has
been established that disturbances in the diastolic
function of the right ventricle progress in parallel
with an increase in the severity of bronchial
asthma [13,14].

Thus, the risk of cardiovascular diseases is closely
related to asthma; disturbances in intracardiac
blood flow in patients with asthma are associated
with the appearance of an obstructive syndrome,
which periodically resolves in the form of changes
in the blood flow of the lungs and pulmonary
circulation. The study of circulatory disorders in
asthma can play an important role in their
treatment.

REFERENCES

1.

Global burden of 369 diseases and injuries in
204 countries and territories, 1990

2019: a

systematic analysis for the Global Burden of
Disease

Study

2019.

Lancet.

2020;396(10258):1204-22

2.

Global Initiative for Asthma. Global Strategy for
Asthma

Management

and

Prevention,

2020.Available from: www.ginasthma.org

3.

Byalovsky Yuri Yulievich, Glotov Sergey
Ivanovich, Rakitina Irina Sergeevna, and
Ermachkova Anna Nikolaevna. "Pathogenetic
aspects of phenotyping bronchial asthma"
Russian Medical and Biological Bulletin named


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN

2689-1026)

VOLUME 06 ISSUE09

44

https://www.theamericanjournals.com/index.php/tajmspr

after Academician I. P. Pavlov, vol. 32, no. 1,
2024,

pp.

145-158.

doi:10.17816/PAVLOVJ181606

4.

Rudenko К.А., Tuguz А.R., Tatarkova E.A. C

-

589T IL-4 gene polymorphism in the
pathogenesis of bronchial asthma. Vyatskii
Meditsinskii Vestnik = Medical Newsletter of
Vyatka. 2021;2(70): 42-47.

5.

Ryabova A.Yu., Shapovalova T.G., Shashina
M.M., Lekareva L.I., Kudishina M.M. Prediction
of cardiac remodeling in patients with
bronchial asthma. Saratov Medical Scientific
Journal 2018; 14 (1): 49

52.

6.

Noskova E.V. , Simonova Zh.G., and Balandina
Yu.A. "PREDICTION OF HEART RHYTHM
DISORDERS IN PATIENTS WITH BRONCHIAL
ASTHMA IN COMBINATION WITH CORONARY
HEART DISEASE USING A LOGIT REGRESSION
MODEL" Vyatka Medical Bulletin, vol. 82, no. 2,
2024, pp. 31-38. doi:10.24412/2220-7880-
2024-2-31-38

7.

Kreslová M, Kirchnerová O, Rajdl D, Sudová V,

Blažek J, Sýkorová A, Jehlička P, Trefil L,
Schwarz J, Pomahačová R, Sýkora J. Bronchial

Asthma as a Cardiovascular Risk Factor: A
Prospective

Observational

Study.

Biomedicines. 2022 Oct 18;10(10):2614. doi:
10.3390/biomedicines10102614.

8.

Kreslová M., Sýkorová A., Bittenglová R.,

Schwarz J., Pomahačová R., Jehlička P., Kobr J.,

Trefil L., Sýkora J. Age-Related Progression of
Microvascular Dysfunction in Cystic Fibrosis:
New Detection Ways and Clinical Outcomes.
Physiol.

Res.

2021;70:893

903.

doi:

10.33549/physiolres.934743.

9.

Savin IA, Zenkova MA, Sen'kova AV. Bronchial
Asthma, Airway Remodeling and Lung Fibrosis
as Successive Steps of One Process. Int J Mol
Sci.

2023

Nov

7;24(22):16042.

doi:

10.3390/ijms242216042.

10.

Stern J., Pier J., Litonjua A.A. Asthma
epidemiology and risk factors. Semin.
Immunopathol.

2020;42:5

15.

doi:

10.1007/s00281-020-00785-1.

11.

De-Paula CR, Magalhães GS, Jentzsch NS,
Botelho CF, Mota CCC, Murça TM, Ramalho LFC,
Tan TC, Capuruço CAB, Rodrigues-Machado
MDG. Echocardiographic Assessment of
Ventricular Function in Young Patients with
Asthma.

Arq

Bras

Cardiol.

2018

Mar;110(3):231-239.

doi:

10.5935/abc.20180052.

12.

Hołda MK, Szczepanek E, Bielawska J,

Palka N,

Wojtysiak D, Frączek P, Nowakowski M,
Sowińska N, Arent Z, Podolec P, Kopeć G.

Changes in heart morphometric parameters
over the course of a monocrotaline-induced
pulmonary arterial hypertension rat model. J
Transl Med. 2020 Jun 30;18(1):262. doi:
10.1186/s12967-020-02440-7.

13.

Dayer N, Ltaief Z, Liaudet L, Lechartier B,
Aubert JD, Yerly P. Pressure Overload and
Right

Ventricular

Failure:

From

Pathophysiology to Treatment. J Clin Med.
2023

Jul

17;12(14):4722.

doi:

10.3390/jcm12144722.

14.

Liu H., Fu Y., Wang K. Asthma and Risk of
Coronary Heart Disease. Ann. Allergy Asthma
Immunol.

2017;118:689

695.

doi:

10.1016/j.anai.2017.03.012.

References

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020.Available from: www.ginasthma.org

Byalovsky Yuri Yulievich, Glotov Sergey Ivanovich, Rakitina Irina Sergeevna, and Ermachkova Anna Nikolaevna. "Pathogenetic aspects of phenotyping bronchial asthma" Russian Medical and Biological Bulletin named after Academician I. P. Pavlov, vol. 32, no. 1, 2024, pp. 145-158. doi:10.17816/PAVLOVJ181606

Rudenko К.А., Tuguz А.R., Tatarkova E.A. C-589T IL-4 gene polymorphism in the pathogenesis of bronchial asthma. Vyatskii Meditsinskii Vestnik = Medical Newsletter of Vyatka. 2021;2(70): 42-47.

Ryabova A.Yu., Shapovalova T.G., Shashina M.M., Lekareva L.I., Kudishina M.M. Prediction of cardiac remodeling in patients with bronchial asthma. Saratov Medical Scientific Journal 2018; 14 (1): 49–52.

Noskova E.V. , Simonova Zh.G., and Balandina Yu.A. "PREDICTION OF HEART RHYTHM DISORDERS IN PATIENTS WITH BRONCHIAL ASTHMA IN COMBINATION WITH CORONARY HEART DISEASE USING A LOGIT REGRESSION MODEL" Vyatka Medical Bulletin, vol. 82, no. 2, 2024, pp. 31-38. doi:10.24412/2220-7880-2024-2-31-38

Kreslová M, Kirchnerová O, Rajdl D, Sudová V, Blažek J, Sýkorová A, Jehlička P, Trefil L, Schwarz J, Pomahačová R, Sýkora J. Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study. Biomedicines. 2022 Oct 18;10(10):2614. doi: 10.3390/biomedicines10102614.

Kreslová M., Sýkorová A., Bittenglová R., Schwarz J., Pomahačová R., Jehlička P., Kobr J., Trefil L., Sýkora J. Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes. Physiol. Res. 2021;70:893–903. doi: 10.33549/physiolres.934743.

Savin IA, Zenkova MA, Sen'kova AV. Bronchial Asthma, Airway Remodeling and Lung Fibrosis as Successive Steps of One Process. Int J Mol Sci. 2023 Nov 7;24(22):16042. doi: 10.3390/ijms242216042.

Stern J., Pier J., Litonjua A.A. Asthma epidemiology and risk factors. Semin. Immunopathol. 2020;42:5–15. doi: 10.1007/s00281-020-00785-1.

De-Paula CR, Magalhães GS, Jentzsch NS, Botelho CF, Mota CCC, Murça TM, Ramalho LFC, Tan TC, Capuruço CAB, Rodrigues-Machado MDG. Echocardiographic Assessment of Ventricular Function in Young Patients with Asthma. Arq Bras Cardiol. 2018 Mar;110(3):231-239. doi: 10.5935/abc.20180052.

Hołda MK, Szczepanek E, Bielawska J, Palka N, Wojtysiak D, Frączek P, Nowakowski M, Sowińska N, Arent Z, Podolec P, Kopeć G. Changes in heart morphometric parameters over the course of a monocrotaline-induced pulmonary arterial hypertension rat model. J Transl Med. 2020 Jun 30;18(1):262. doi: 10.1186/s12967-020-02440-7.

Dayer N, Ltaief Z, Liaudet L, Lechartier B, Aubert JD, Yerly P. Pressure Overload and Right Ventricular Failure: From Pathophysiology to Treatment. J Clin Med. 2023 Jul 17;12(14):4722. doi: 10.3390/jcm12144722.

Liu H., Fu Y., Wang K. Asthma and Risk of Coronary Heart Disease. Ann. Allergy Asthma Immunol. 2017;118:689–695. doi: 10.1016/j.anai.2017.03.012.